Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Medicine Reports Positive Data for HER2 Treatment in Pretreated Patients

publication date: Dec 12, 2019

Zhejiang Medicine and its majority owned subsidiary, NovoCodex, announced positive early results from a China Phase I trial of an anti-HER2 ADC in heavily pretreated patients with metastatic HER2 positive breast cancer. At the highest dose tested before data cutoff, ARX788 achieved a 63% overall response rate. The candidate targets human epidermal growth factor receptor 2 and causes apoptosis. ARX788 was developed by Ambrx of San Diego and in-licensed by NovoCodex, which is in charge of Phase I development. In return, NovoCodex is eligible to receive a royalty on non-China revenues. More details...

Stock Symbol: (SHA: 600216)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here